Meanwhile, treatment of EGFR-mutant NSCLC cells with the STAT3 inhibitor TPCA-1 enhanced the anti-proliferative effects of afatinib chemotherapy [274]. Here, STAT3 is linked to non-small cell lung carcinoma.